Annual General Meeting brought forward to March 30 2015

The Board of NeuroVive Pharmaceutical AB (publ) has decided to bring forward the Annual General Meeting 2015 to Monday 30 March, 2015, at 4 p.m. at Medicon Village, Scheelevägen 2, in Lund, Sweden to be able to focus on matters connected with the CIRCUS-study during the latter part of spring. 

Shareholders are entitled to have a matter addressed by the Annual General Meeting as long as their request has been received by the Board of Directors by 9 February 2015. The Board of Directors can be contacted by email at: styrelsen@neurovive.com, or by mail at: NeuroVive Pharmaceutical AB, FAO: Greg Batcheller, Medicon Village, 223 81 Lund, Sweden.

Shareholders wishing to propose members of the Nomination Committee can contact the Committee by email at: valberedningen@neurovive.com, or by mail at: NeuroVive Pharmaceutical AB, FAO: Nomination Committee, Medicon Village, 223 81 Lund, Sweden. In order for the Nomination Committee to consider the proposals received with due care, proposals must be received by the Nomination Committee by no later than 2 February 2015.

About NeuroVive Pharmaceutical

NeuroVive Pharmaceutical AB (publ), a leading mitochondrial medicine company, is developing a portfolio of products to treat acute cardiovascular and neurological conditions through mitochondrial protection. These medical conditions are characterized by a pressing medical need and have no approved pharmaceutical treatment options at present. NeuroVive’s products CicloMulsion® (heart attack) and NeuroSTAT® (traumatic brain injury) are currently being evaluated in phase III and phase II studies, respectively. NeuroVive’s research programs also include products for the treatment of antiviral indications (Hepatitis B/C), brain cell injury in stroke patients, and drug candidates for cellular protection and treating mitochondria-related energy regulation diseases. NeuroVive’s shares are listed on NASDAQ OMX, Stockholm, Sweden.

For Investor Relations and media questions, please contact:
Ingmar Rentzhog, Laika Consulting, Tel: +46 (0)46 275 62 21 or ir@neurovive.se
It is also possible to arrange an interview with NeuroVive’s CEO Mikael Brönnegård at the above contact.

NeuroVive Pharmaceutical AB (publ)
Medicon Village, SE-223 81 Lund, Sweden
Tel: +46 (0)46 275 62 20 (switchboard), Fax: +46 (0)46 888 83 48
info@neurovive.se, www.neurovive.se

NeuroVive Pharmaceutical AB (publ) is required to publish the information in this news release under The Swedish Securities Market Act. The information was submitted for publication on 12 January 2015, at 14.00 p.m. CET. 

NeuroVive Pharmaceutical AB (publ) -  the mitochondrial medicine company. The company is listed on NASDAQ OMX Stockholm, Small Cap, under the ticker symbol NVP. The share is also traded on the OTC market in the US.  NeuroVive Pharmaceutical (OTC: NEVPF) trades on the OTC Grey Market. Investors can find Real-Time quotes and market information for the company at  www. otc markets.com/stock/ NEVPF /quote  


About Us

NeuroVive Pharmaceutical AB is a leader in mitochondrial medicine, with one project in clinical phase II development for the prevention of moderate to severe traumatic brain injury (NeuroSTAT®) and one project in clinical phase I (KL1333) for genetic mitochondrial diseases. The R&D portfolio consists of several late stage research programs in areas ranging from genetic mitochondrial disorders to cancer and metabolic diseases such as NASH. The company’s strategy is to advance drugs for rare diseases through clinical development and into the market. The strategy for projects within larger indications outside the core focus area is out-licensing in the preclinical phase. NeuroVive is listed on Nasdaq Stockholm, Sweden (ticker: NVP). The share is also traded on the OTCQX Best Market in the US (OTC: NEVPF). www.neurovive.com

Subscribe

Documents & Links